EX-99.1 2 g23273exv99w1.htm EX-99.1 exv99w1
Exhibit 99.1
(EMDEON LOGO)
FOR IMMEDIATE RELEASE
Emdeon Reports First Quarter 2010 Results
    7.9% Revenue Growth Over First Quarter 2009
 
    9.3% Increase in Adjusted EBITDA Over First Quarter 2009
NASHVILLE, Tenn. (May 6, 2010) — Emdeon Inc. (NYSE: EM), a leading provider of healthcare revenue and payment cycle management solutions, today announced financial results for the first quarter ended March 31, 2010, as summarized below:
                         
($ in millions, except per share amounts)   1Q10   1Q09   % Change
Revenue
  $ 237.3     $ 219.9       7.9 %
Net Income
  $ 4.3     $ 3.3       29.6 %
Net Income per share (diluted)
  $ 0.02     $ 0.02       0.0 %
Non-GAAP Adjusted EBITDA
  $ 62.4     $ 57.0       9.3 %
Non-GAAP Adjusted Net Income per fully diluted share
  $ 0.21     $ 0.21       0.0 %
Non-GAAP fully diluted shares
    121.3       106.1          
First quarter revenue was $237.3 million, an increase of 7.9%, compared to $219.9 million for the same period in the prior year. GAAP operating income for the first quarter of 2010 was $30.8 million compared to $28.8 million for the same period last year. First quarter Adjusted EBITDA grew 9.3% to $62.4 million, or 26.3% of revenue, from Adjusted EBITDA of $57.0 million, or 25.9% of revenue, in the comparable period last year.
GAAP net income (before noncontrolling interest) for the first quarter of 2010 was $4.3 million compared to GAAP net income of $3.3 million for the same period last year. GAAP net income per diluted share for the first quarter of 2010 was $0.02 compared to $0.02 in the same period last year. Adjusted Net Income per fully diluted share for the first quarter of 2010 was $0.21, using a weighted average share count of 121.3 million, compared to $0.21, using a weighted average share count of 106.1 million, for the same period last year.
“Emdeon is off to a good start to the year and delivered solid financial results for the first quarter,” said George Lazenby, Emdeon’s chief executive officer. “We are also excited about the growing momentum of our emerging business initiatives, including our provider ePayment solutions and healthcare technology consulting services related to our recent FutureVision and HTMS acquisitions. Emdeon remains on track to execute on our 2010 financial goals.”
At March 31, 2010, Emdeon’s cash and cash equivalents totaled $220.4 million. Total long-term debt under Emdeon’s credit facilities was $854.5 million, before unamortized debt discount.

1


 

A reconciliation of Emdeon’s financial results determined in accordance with U.S. Generally Accepted Accounting Principles (GAAP) to certain non-GAAP financial measures has been provided in the financial statement tables included in this release to supplement its unaudited condensed consolidated financial statements presented on a GAAP basis. An explanation of these non-GAAP measures is also included below under the heading “Explanation of Non-GAAP Financial Measures.”
Financial Outlook
Emdeon affirmed its outlook for annual revenue, Adjusted EBITDA and Adjusted Net Income per fully diluted share for 2010 as follows:
    2010 revenue to be between $1.0 to $1.06 billion
 
    2010 Adjusted EBITDA to be between $266 to $278 million
 
    2010 Adjusted Net Income per fully diluted share to be between $0.90 to $0.94 using a weighted average share count of 122.4 million
Notice of Conference Call and Webcast
Emdeon will conduct a conference call/webcast for investors and institutional analysts on Thursday, May 6, 2010 at 5:00 pm Eastern Time/4:00 pm Central Time to discuss Emdeon’s financial results.
To access Emdeon’s live conference call and webcast, dial 866-783-2140 (857-350-1599 for international calls) using conference code 75889855 or visit the Investors section of Emdeon’s website: www.emdeon.com. Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software to access the webcast. For those unable to listen to the live broadcast, a conference call replay will be available for one week following the conference call by calling 888-286-8010 (617-801-6888 for international calls) using conference code 83532925. A webcast replay will also be archived on Emdeon’s website for at least 30 days following the conference call.
About Emdeon
Emdeon is a leading provider of revenue and payment cycle management solutions, connecting payers, providers and patients in the U.S. healthcare system. Emdeon’s product and service offerings integrate and automate key business and administrative functions of its payer and provider customers throughout the patient encounter. Through the use of Emdeon’s comprehensive suite of products and services, which are designed to easily integrate with existing technology infrastructures, customers are able to improve efficiency, reduce costs, increase cash flow and more efficiently manage the complex revenue and payment cycle process. For more information, visit www.emdeon.com.
Forward-Looking Statements
Statements made in this press release that express Emdeon’s or management’s intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements, which Emdeon intends to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. These statements often include words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions.

2


 

Forward-looking statements may include information concerning Emdeon’s possible or assumed future results of operations, including descriptions of Emdeon’s revenues, profitability, outlook and overall business strategy. You should not place undue reliance on these statements because they are subject to numerous uncertainties and factors relating to Emdeon’s operations and business environment, all of which are difficult to predict and many of which are beyond Emdeon’s control. Although Emdeon believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect Emdeon’s actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements, including but not limited to: effects of competition, including competition from entities that are customers for certain of Emdeon’s products and services; Emdeon’s ability to maintain relationships with its customers and channel partners; Emdeon’s ability to effectively cross-sell its products and services to existing customers and to continue to generate revenue and maintain profitability by developing and successfully deploying new or updated products and services; pricing pressures on Emdeon’s products and services; the anticipated benefits from acquisitions not being fully realized or not being realized within the expected time frames; and general economic, business or regulatory conditions affecting the healthcare information technology and services industries; as well as the other risks discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections and elsewhere in Emdeon’s Annual Report on Form 10-K for the year ended December 31, 2009, as well as Emdeon’s periodic and other reports, filed with the Securities and Exchange Commission.
You should keep in mind that any forward-looking statement made by Emdeon herein, or elsewhere, speaks only as of the date on which made. Emdeon expressly disclaims any intent, obligation or undertaking to update or revise any forward-looking statements made herein to reflect any change in Emdeon’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
# # #
Contacts:
Investor Relations

Tommy Lewis
615.932.3235
tlewis@emdeon.com

3


 

Emdeon Inc.
Condensed Consolidated Statements of Operations
(unaudited and amounts in thousands, except share and per share amounts)
                 
    For the Three Months  
    Ended March 31,  
    2010     2009  
Revenue
  $ 237,279     $ 219,885  
Costs and expenses:
               
Cost of operations (exclusive of depreciation and amortization below)
    143,986       134,739  
Development and engineering
    8,554       7,075  
Sales, marketing, general and administrative
    26,119       24,160  
Depreciation and amortization
    27,775       25,098  
 
           
Operating income
    30,845       28,813  
Interest income
    (3 )     (21 )
Interest expense
    15,665       17,942  
Other
    290        
 
           
Income before income tax provision
    14,893       10,892  
Income tax provision
    10,630       7,602  
 
           
Net income
    4,263       3,290  
Net income attributable to noncontrolling interest
    2,374       2,072  
 
           
Net income attributable to Emdeon Inc.
  $ 1,889     $ 1,218  
 
           
Net income per share Class A common stock:
               
Basic
  $ 0.02     $ 0.02  
 
           
Diluted
  $ 0.02     $ 0.02  
 
           
Weighted average common shares outstanding:
               
Basic
    90,461,968       77,413,610  
 
           
Diluted
    90,468,057       77,413,610  
 
           

4


 

Emdeon Inc.
Condensed Consolidated Balance Sheets
(unaudited and amounts in thousands, except share amounts)
                 
    March 31,     December 31,  
    2010     2009  
Assets
               
Current assets:
               
Cash and cash equivalents
  $ 220,418     $ 211,999  
Accounts receivable, net of allowance for doubtful accounts of $4,543 and $4,433 at March 31, 2010 and December 31, 2009, respectively
    152,646       151,022  
Deferred income tax assets
    4,445       4,924  
Prepaid expenses and other current assets
    15,146       16,632  
 
           
Total current assets
    392,655       384,577  
Property and equipment, net
    175,231       152,091  
Goodwill
    730,819       703,027  
Intangible assets, net
    979,372       989,280  
Other assets, net
    1,380       1,451  
 
           
Total assets
  $ 2,279,457     $ 2,230,426  
 
           
Liabilities and equity
               
Current liabilities:
               
Accounts payable
  $ 8,677     $ 9,910  
Accrued expenses
    81,956       72,493  
Deferred revenues
    12,167       12,153  
Current portion of long-term debt
    10,153       9,972  
 
           
Total current liabilities
    112,953       104,528  
Long-term debt, excluding current portion
    831,726       830,710  
Deferred income tax liabilities
    150,502       145,914  
Tax receivable agreement obligations to related parties
    140,704       142,044  
Other long-term liabilities
    50,725       27,361  
Commitments and contingencies
               
Equity:
               
Preferred stock (par value, $0.00001), 25,000,000 shares authorized and 0 shares issued and outstanding
           
Class A common stock (par value, $0.00001), 400,000,000 shares authorized and 90,618,894 and 90,423,941 shares outstanding at March 31, 2010 and December 31, 2009, respectively
    1       1  
Class B common stock, exchangeable (par value, $0.00001), 52,000,000 shares authorized and 24,689,142 and 24,752,955 shares outstanding at March 31, 2010 and December 31, 2009, respectively
           
Additional paid-in capital
    736,838       730,941  
Accumulated other comprehensive loss
    (9,334 )     (11,198 )
Retained earnings
    35,593       33,704  
 
           
Emdeon Inc. equity
    763,098       753,448  
Noncontrolling interest
    229,749       226,421  
 
           
Total equity
    992,847       979,869  
 
           
Total liabilities and equity
  $ 2,279,457     $ 2,230,426  
 
           

5


 

Emdeon Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited and amounts in thousands)
                 
    For the Three Months  
    Ended March 31,  
    2010     2009  
Operating activities
               
Net income
  $ 4,263     $ 3,290  
Adjustments to reconcile net income to net cash provided by operating activities:
               
Depreciation and amortization
    27,775       25,098  
Equity compensation expense
    3,675       2,576  
Deferred income tax expense
    4,666       2,659  
Amortization of debt discount and issuance costs
    3,135       2,791  
Amortization of discontinued cash flow hedge from other comprehensive loss
    1,453       1,972  
Other
    571       104  
Changes in operating assets and liabilities:
               
Accounts receivable
    3,347       (1,216 )
Prepaid expenses and other
    1,646       6,531  
Accounts payable
    (2,434 )     2,429  
Accrued expenses and other liabilities
    3,173       (5,915 )
Deferred revenues
    14       1,343  
Tax receivable agreement obligations to related parties
    (1,480 )      
 
           
Net cash provided by operating activities
    49,804       41,662  
 
           
Investing activities
               
Purchases of property and equipment
    (12,949 )     (7,055 )
Payments for acquisitions, net of cash acquired
    (26,444 )      
 
           
Net cash used in investing activities
    (39,393 )     (7,055 )
 
           
Financing activities
               
Debt principal payments
    (1,888 )     (17,888 )
Payments on revolver
          (10,000 )
Other
    (104 )     158  
 
           
Net cash used in financing activities
    (1,992 )     (27,730 )
 
           
Net increase in cash and cash equivalents
    8,419       6,877  
Cash and cash equivalents at beginning of period
    211,999       71,478  
 
           
Cash and cash equivalents at end of period
  $ 220,418     $ 78,355  
 
           

6


 

Segment Information
(unaudited and amounts in thousands)
                                         
    For the Three Months Ended March 31, 2010
                            Corporate &    
    Payer   Provider   Pharmacy   Eliminations   Consolidated
Revenue from external customers
                                       
Claims management
  $ 45,476     $     $     $     $ 45,476  
Payment services
    56,820                         56,820  
Patient statements
          66,676                   66,676  
Revenue cycle management
          40,674                   40,674  
Dental
          7,937                   7,937  
Pharmacy services
                19,696             19,696  
Inter-segment revenue
    873       87             (960 )      
     
Net revenue
    103,169       115,374       19,696       (960 )     237,279  
Costs and expenses:
                                       
Cost of operations
    66,817       71,372       6,725       (928 )     143,986  
Development and engineering
    3,015       3,824       1,715             8,554  
Sales, marketing, general and administrative
    6,873       6,816       1,558       10,872       26,119  
     
Segment contribution (1)
  $ 26,464     $ 33,362     $ 9,698     $ (10,904 )     58,620  
     
Depreciation and amortization
                                    27,775  
Interest income
                                    (3 )
Interest expense
                                    15,665  
Other loss
                                    290  
 
                                       
Income before income tax provision
                                  $ 14,893  
 
                                       
                                         
    For the Three Months Ended March 31, 2009
                            Corporate &    
    Payer   Provider   Pharmacy   Eliminations   Consolidated
Revenue from external customers
                                       
Claims management
  $ 45,112     $     $     $     $ 45,112  
Payment services
    50,346                         50,346  
Patient statements
          68,672                   68,672  
Revenue cycle management
          37,746                   37,746  
Dental
          7,760                   7,760  
Pharmacy services
                10,249             10,249  
Inter-segment revenue
    70       464             (534 )      
     
Net revenue
    95,528       114,642       10,249       (534 )     219,885  
Costs and expenses:
                                       
Cost of operations
    59,876       73,434       1,849       (420 )     134,739  
Development and engineering
    2,632       3,422       1,021             7,075  
Sales, marketing, general and administrative
    5,854       7,492       978       9,836       24,160  
     
Segment contribution (1)
  $ 27,166     $ 30,294     $ 6,401     $ (9,950 )     53,911  
     
Depreciation and amortization
                                    25,098  
Interest income
                                    (21 )
Interest expense
                                    17,942  
 
                                       
Income before income tax provision
                                  $ 10,892  
 
                                       
 
(1)   Segment contribution has been reduced by equity-based compensation expense of $3,675 and $2,576 for the three months ended March 31, 2010 and 2009, respectively. Segment contribution without such equity-based compensation expense would have been $62,295 and $56,487 for the three months ended March 31, 2010 and 2009, respectively.

7


 

Explanation of Non-GAAP Financial Measures
Emdeon’s management team believes that in order to properly understand Emdeon’s short-term and long-term financial trends, investors may wish to consider the impact of certain non-cash or non-operating items, when used as a supplement to financial performance measures prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). These items result from facts and circumstances that vary in frequency and/or impact continuing operations. In addition, management uses results of operations before such excluded items to evaluate the operational performance of Emdeon as a basis for strategic planning and, in the case of Adjusted EBITDA, as a performance evaluation metric in determining achievement of certain executive and management incentive compensation programs. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition to the description provided below, reconciliations of GAAP to non-GAAP results are provided in the financial statement tables included in this release.
In this release, Emdeon defines Adjusted EBITDA as EBITDA (which is defined as net income before net interest expense, income tax provision (benefit) and depreciation and amortization), plus certain other non-cash or non-operating items (collectively, “EBITDA Adjustments”).
In this release, Emdeon defines Adjusted Net Income as the sum of (i) GAAP net income, (ii) EBITDA Adjustments, (iii) non-cash interest expense and (iv) depreciation and amortization expense resulting from adjustments of assets to fair value in connection with acquisition accounting, less income taxes computed based on a normalized income tax rate. Emdeon defines Adjusted Net Income per fully diluted share as the quotient of Adjusted Net Income and weighted average shares outstanding, assuming all potentially dilutive securities are fully dilutive and outstanding shares from their date of grant or issuance.
To properly evaluate Emdeon’s business, Emdeon encourages investors to review the GAAP financial information included in this release, and not rely on any single financial measure to evaluate Emdeon’s business. Emdeon also strongly encourages investors to review the reconciliation of GAAP net income and GAAP net income per diluted share to the applicable non-GAAP measures of Adjusted EBITDA, Adjusted Net Income and Adjusted Net Income per fully diluted share. These non-GAAP measures, as Emdeon defines them, may not be similar to non-GAAP measures used by other companies.
Management uses Adjusted EBITDA and Adjusted Net Income per fully diluted share to facilitate a comparison of Emdeon’s operating performance on a consistent basis from period to period that, when viewed in combination with Emdeon’s GAAP results, management believes provides a more complete understanding of factors and trends affecting Emdeon’s business than GAAP measures alone. Management believes these non-GAAP measures assist Emdeon’s board of directors, management, lenders and investors in comparing Emdeon’s operating performance on a consistent basis because they remove where applicable, the impact of Emdeon’s capital and organizational structure, asset base, acquisition accounting, non-cash charges and non-operating items from Emdeon’s operations.
Emdeon also presents Adjusted EBITDA and Adjusted Net Income per fully diluted share on a forward-looking basis as part of its Financial Outlook for 2010. Emdeon is unable to present a quantitative reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because management cannot predict, with sufficient

8


 

reliability, contingent payments relating to past and possible future acquisitions, changes in the fair value of Emdeon’s interest rate swap agreement and the effect on income taxes of these and other items attributable to Emdeon’s organizational structure, which are difficult to estimate and primarily dependent on future events.

9


 

Emdeon Inc.
Reconciliation of GAAP Net Income to Adjusted EBITDA
(unaudited and amounts in thousands)
                 
    For the Three Months  
    Ended March 31,  
    2010     2009  
Net income
  $ 4,263     $ 3,290  
Interest expense, net
    15,662       17,921  
Income tax provision
    10,630       7,602  
Depreciation and amortization
    27,775       25,098  
 
           
EBITDA
    58,330       53,911  
 
               
Equity-based compensation
    3,675       2,576  
Purchase accounting adjustments
    176       473  
Facilities consolidation costs
    430       85  
Acquisition and divestiture related costs
    939        
Tax receivable agreements change in estimate
    (1,480 )      
Non-operating loss
    290        
 
           
EBITDA Adjustments
    4,030       3,134  
 
           
 
               
Adjusted EBITDA
  $ 62,360     $ 57,045  
 
           
Emdeon Inc.
Reconciliation of GAAP Net Income to Adjusted Net Income
(unaudited and amounts in thousands)
                 
    For the Three Months  
    Ended March 31,  
    2010     2009  
Net income
  $ 4,263     $ 3,290  
Income tax provision
    10,630       7,602  
EBITDA Adjustments
    4,030       3,134  
Non-cash interest expense
    4,588       4,763  
Depreciation and amortization resulting from acquisition method adjustments
    19,176       18,766  
 
           
 
               
Adjusted net income before income taxes
    42,687       37,555  
Normalized income tax provision
    16,861       14,834  
 
           
 
               
Adjusted Net Income
  $ 25,826     $ 22,721  
 
           

10


 

Emdeon Inc.
Reconciliation of Diluted Net Income Per Diluted Share of Class A Common Stock to
Adjusted Net Income Per Fully Diluted Share
(1)
(unaudited)
                 
    For the Three Months  
    Ended March 31,  
    2010     2009  
Diluted net income per share Class A common stock
  $ 0.02     $ 0.02  
Impact of assuming full dilution of all outstanding equity instruments for the period
    0.01       0.01  
Adjustments on a per share basis:
               
Income tax provision
    0.09       0.07  
EBITDA Adjustments
    0.03       0.03  
Non-cash interest expense
    0.04       0.04  
Depreciation and amortization resulting from acquisition method adjustments
    0.16       0.18  
 
           
 
               
Adjusted net income before income taxes
    0.35       0.35  
Normalized income tax provision
    0.14       0.14  
 
           
Adjusted Net Income per fully diluted share
  $ 0.21     $ 0.21  
 
           
 
(1)   The calculation of Adjusted Net Income per fully diluted share assumes the following equity-based instruments were fully converted into Class A common stock on their date of issuance:
                 
    (shares in thousands)  
    For the Three Months  
    Ended March 31,  
Weighted average of:   2010     2009  
Class A shares outstanding
    90,462       77,414  
Class B shares outstanding
    24,725       24,749  
Restricted stock units outstanding
    572       924  
Options to purchase Class A shares outstanding
    5,536       3,060  
 
           
Shares assumed in Adjusted Net Income per fully diluted share calculation
    121,295       106,147  
 
           

11